{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:43:27Z","timestamp":1786175007614,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hasten Biopharmaceutical Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00813-9","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:42:59Z","timestamp":1786167779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-7708","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Tjong A","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"10159","key":"813_CR1","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"GRF Collaborators","year":"2018","unstructured":"Collaborators GRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923\u201394.","journal-title":"Lancet"},{"key":"813_CR2","unstructured":"WHO. Global report on hypertension: the race against a silent killer. https:\/\/www.who.int\/teams\/noncommunicable-diseases\/hypertension-report."},{"issue":"3","key":"813_CR3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41440-024-02070-2","volume":"48","author":"J Liu","year":"2025","unstructured":"Liu J. Highlights of the 2024 Chinese hypertension guidelines. Hypertens Res. 2025;48(3):1048\u201353.","journal-title":"Hypertens Res"},{"issue":"19","key":"813_CR4","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"key":"813_CR5","doi-asserted-by":"crossref","unstructured":"Miura S-i, Saku K. Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers. Hypertens Res. 2014;37(9):799\u2013800.","DOI":"10.1038\/hr.2014.118"},{"issue":"3","key":"813_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41371-018-0138-y","volume":"33","author":"C Dimou","year":"2019","unstructured":"Dimou C, Antza C, Akrivos E, et al. A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension. J Hum Hypertens. 2019;33(3):188\u2013201.","journal-title":"J Hum Hypertens"},{"issue":"10","key":"813_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1253\/circrep.CR-20-0076","volume":"2","author":"T Nakajima","year":"2020","unstructured":"Nakajima T, Oh A, Saita S, et al. Comparative effectiveness of angiotensin II receptor blockers in patients with hypertension in Japan - systematic review and network meta-analysis. Circ Reports. 2020;2(10):576\u201386.","journal-title":"Circ Reports."},{"issue":"6","key":"813_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.hlc.2017.06.721","volume":"27","author":"B Tsoi","year":"2018","unstructured":"Tsoi B, Akioyamen LE, Bonner A, et al. Comparative efficacy of angiotensin II antagonists in essential hypertension: systematic review and network meta-analysis of randomised controlled trials. Heart Lung Circ. 2018;27(6):666\u201382.","journal-title":"Heart Lung Circ"},{"issue":"2","key":"813_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65(2):809\u201348.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"813_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/mol.115.099176","volume":"88","author":"T Takezako","year":"2015","unstructured":"Takezako T, Unal H, Karnik SS, et al. Structure-function basis of attenuated inverse agonism of angiotensin II type 1 receptor blockers for active-state angiotensin II type 1 receptor. Mol Pharmacol. 2015;88(3):488\u2013501.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"813_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s11096-024-01755-5","volume":"46","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yang H, Guo H. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis. Int J Clin Pharm. 2024;46(5):1034\u201343.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"813_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/hr.2012.166","volume":"36","author":"K Tamura","year":"2013","unstructured":"Tamura K, Ohsawa M, Kanaoka T, et al. What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension? Hypertens Res. 2013;36(2):107\u20138.","journal-title":"Hypertens Res"},{"issue":"1","key":"813_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","volume":"38","author":"HMA Abraham","year":"2015","unstructured":"Abraham HMA, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38(1):33\u201354.","journal-title":"Drug Saf"},{"issue":"12","key":"813_CR14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/hr.2010.182","volume":"33","author":"L Li","year":"2010","unstructured":"Li L, Zhou N, Gong H, et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res. 2010;33(12):1289\u201397.","journal-title":"Hypertens Res"},{"issue":"12","key":"813_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"813_CR16","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1007\/s12325-024-02997-5","volume":"41","author":"J Qian","year":"2024","unstructured":"Qian J, Zhang M, Chen Z. A systematic literature review and network meta-analysis of azilsartan medoxomil compared to other anti-hypertensives efficacy in lowering blood pressure amongst mild to moderate hypertensive patients. Adv Ther. 2024;41(12):4498\u2013517.","journal-title":"Adv Ther"},{"key":"813_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CE.S81776","volume":"11","author":"E Angeloni","year":"2016","unstructured":"Angeloni E. Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. Core Evid. 2016;11:1\u201310.","journal-title":"Core Evid."},{"key":"813_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1824621","volume":"2019","author":"A Pradhan","year":"2019","unstructured":"Pradhan A, Tiwari A, Sethi R. Azilsartan: current evidence and perspectives in management of hypertension. Int J Hypertens. 2019;2019:1\u20138.","journal-title":"Int J Hypertens"},{"issue":"2","key":"813_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/hr.2012.147","volume":"36","author":"S-I Miura","year":"2013","unstructured":"Miura S-I, Okabe A, Matsuo Y, et al. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res. 2013;36(2):134\u20139.","journal-title":"Hypertens Res"},{"key":"813_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2717291","volume":"2022","author":"C Deerochanawong","year":"2022","unstructured":"Deerochanawong C, Chang KC, Woo YC, et al. A prospective study of azilsartan medoxomil in the treatment of patients with essential hypertension and type 2 diabetes in Asia. Int J Hypertens. 2022;2022:1\u20139.","journal-title":"Int J Hypertens"},{"issue":"1","key":"813_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26599\/1671-5411.2025.01.008","volume":"22","author":"J-G Wang","year":"2024","unstructured":"Wang J-G. Chinese guidelines for the prevention and treatment of hypertension (2024 revision). J Geriatr Cardiol. 2024;22(1):1\u2013149.","journal-title":"J Geriatr Cardiol"},{"key":"813_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"813_CR23","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). http:\/\/www.training.cochrane.org\/handbook."},{"key":"813_CR24","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928\u2013d5928.","DOI":"10.1136\/bmj.d5928"},{"issue":"2","key":"813_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"813_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"10","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, et al. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;10(4):569\u201381.","journal-title":"Res Synth Methods."},{"key":"813_CR27","unstructured":"Xin Y CN, Owen RK, Freeman S, Sutton AJ. MetaInsight User Guide\u2014(including Bayesian functionality) Version 1.1 https:\/\/crsu.shinyapps.io\/MetaInsight\/."},{"issue":"5","key":"813_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/jch.14227","volume":"23","author":"JG Wang","year":"2021","unstructured":"Wang JG, Zhang M, Feng YQ, et al. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2021;23(5):901\u201314.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"813_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/jpet.110.176636","volume":"336","author":"M Ojima","year":"2011","unstructured":"Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336(3):801\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"813_CR30","doi-asserted-by":"publisher","first-page":"R71","DOI":"10.1530\/JME-14-0125","volume":"53","author":"P Balakumar","year":"2014","unstructured":"Balakumar P, Jagadeesh G. Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. J Mol Endocrinol. 2014;53(2):R71-92.","journal-title":"J Mol Endocrinol"},{"issue":"49","key":"813_CR31","doi-asserted-by":"publisher","first-page":"29127","DOI":"10.1074\/jbc.M115.689000","volume":"290","author":"H Zhang","year":"2015","unstructured":"Zhang H, Unal H, Desnoyer R, et al. Structural basis for ligand recognition and functional selectivity at angiotensin receptor. J Biol Chem. 2015;290(49):29127\u201339.","journal-title":"J Biol Chem"},{"key":"813_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.phrs.2017.06.013","volume":"123","author":"T Takezako","year":"2017","unstructured":"Takezako T, Unal H, Karnik SS, et al. Current topics in angiotensin II type 1 receptor research: focus on inverse agonism, receptor dimerization and biased agonism. Pharmacol Res. 2017;123:40\u201350.","journal-title":"Pharmacol Res"},{"key":"813_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/VHRM.S22595","volume":"8","author":"TW Kurtz","year":"2012","unstructured":"Kurtz TW, Kajiya T. Differential pharmacology and benefit\/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133\u201343.","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"813_CR34","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/MS9.0000000000001547","volume":"86","author":"QA Khan","year":"2024","unstructured":"Khan QA, Sharma S, ul Mulk I, et al. Effect of azilsartan on clinical blood pressure reduction compared to other angiotensin receptor blockers: a systematic review and meta-analysis. Ann Med Surg (Lond). 2024;86(2):958\u201367.","journal-title":"Ann Med Surg (Lond)"},{"key":"813_CR35","doi-asserted-by":"crossref","unstructured":"Shrestha AB, Singh H, Yadav RS, et al. Efficacy and safety of combinations of azilsartan- medoximil\/chlorthalidone versus olmesartan-medoximil\/hydrochlorothiazide among hypertensive patients: a meta- analysis [abstract]. American Thoracic Society International Conference. Am J Respir Crit Care Med. 2024.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A5732"},{"issue":"26","key":"813_CR36","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/eurheartj\/eht333","volume":"35","author":"H Makani","year":"2014","unstructured":"Makani H, Bangalore S, Supariwala A, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J. 2014;35(26):1732\u201342.","journal-title":"Eur Heart J"},{"key":"813_CR37","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u2014updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613\u2013622.","DOI":"10.1097\/HJH.0000000000000881"},{"key":"813_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108945","volume":"277","author":"P Balakumar","year":"2026","unstructured":"Balakumar P, Mulukuri N, Jagadeesh G. A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation. Pharmacol Ther. 2026;277:108945.","journal-title":"Pharmacol Ther"},{"key":"813_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/B978-0-12-381296-4.00002-6","volume":"485","author":"H Akazawa","year":"2010","unstructured":"Akazawa H, Yasuda N, Miura S, et al. Assessment of inverse agonism for the angiotensin II type 1 receptor. Methods Enzymol. 2010;485:25\u201335.","journal-title":"Methods Enzymol"},{"issue":"1","key":"813_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/me.2007-0312","volume":"22","author":"S Miura","year":"2008","unstructured":"Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol. 2008;22(1):139\u201346.","journal-title":"Mol Endocrinol"},{"issue":"4","key":"813_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","volume":"63","author":"K Kario","year":"2014","unstructured":"Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698\u2013705.","journal-title":"Hypertension"},{"issue":"3","key":"813_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","volume":"57","author":"WB White","year":"2011","unstructured":"White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413\u201320.","journal-title":"Hypertension"},{"issue":"6","key":"813_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/01.HYP.25.6.1345","volume":"25","author":"AH Gradman","year":"1995","unstructured":"Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25(6):1345\u201350.","journal-title":"Hypertension"},{"issue":"3","key":"813_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1524-6175.2007.06395.x","volume":"9","author":"TD Giles","year":"2007","unstructured":"Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187\u201395.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"813_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","volume":"13","author":"GL Bakris","year":"2011","unstructured":"Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10","key":"813_CR46","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jch.14570","volume":"24","author":"KC Sung","year":"2022","unstructured":"Sung KC, Sung JH, Cho EJ, et al. Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. J Clin Hypertens (Greenwich). 2022;24(10):1298\u2013309.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"32","key":"813_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021465","volume":"99","author":"J Wu","year":"2020","unstructured":"Wu J, Du X, Lv Q, et al. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. Medicine (Baltimore). 2020;99(32):e21465.","journal-title":"Medicine (Baltimore)"},{"issue":"9722","key":"813_CR48","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255\u201366.","journal-title":"Lancet"},{"issue":"6","key":"813_CR49","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12325-012-0029-5","volume":"29","author":"HA Punzi","year":"2012","unstructured":"Punzi HA, Lewin A, Li W, et al. Efficacy\/safety of olmesartan medoxomil versus losartan potassium in na\u00efve versus previously treated subjects with hypertension. Adv Ther. 2012;29(6):524\u201337.","journal-title":"Adv Ther"},{"issue":"8","key":"813_CR50","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41440-023-01326-7","volume":"46","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang W, Yan J, et al. Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study. Hypertens Res. 2023;46(8):2024\u201332.","journal-title":"Hypertens Res"},{"issue":"2","key":"813_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40885-018-0086-4","volume":"24","author":"A Juhasz","year":"2018","unstructured":"Juhasz A, Wu J, Hisada M, et al. Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension. Clin Hypertens. 2018;24(2):1\u201311.","journal-title":"Clin Hypertens"},{"key":"813_CR52","doi-asserted-by":"crossref","unstructured":"Lacourci\u00e8re Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan\/Losartan study investigators. Am J Hypertens. 1999;12(12 Pt 1-2):1181\u20131187.","DOI":"10.1016\/S0895-7061(99)00142-9"},{"key":"813_CR53","doi-asserted-by":"crossref","unstructured":"Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12(12):861\u2013866.","DOI":"10.1038\/sj.jhh.1000718"},{"issue":"1","key":"813_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","volume":"20","author":"JL Pool","year":"2007","unstructured":"Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11\u201320.","journal-title":"Am J Hypertens"},{"issue":"1","key":"813_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clinthera.2007.01.007","volume":"29","author":"JL Pool","year":"2007","unstructured":"Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan\/hydrochlorothiazide combination therapy at doses up to 320\/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29(1):61\u201373.","journal-title":"Clin Ther"},{"issue":"4","key":"813_CR56","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"T Philipp","year":"2007","unstructured":"Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563\u201380.","journal-title":"Clin Ther"},{"issue":"4","key":"813_CR57","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","volume":"30","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587\u2013604.","journal-title":"Clin Ther"},{"issue":"4","key":"813_CR58","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2165\/00129784-200909040-00001","volume":"9","author":"SG Chrysant","year":"2009","unstructured":"Chrysant SG, Chavanu KJ, Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9(4):241\u201351.","journal-title":"Am J Cardiovasc Drugs"},{"key":"813_CR59","doi-asserted-by":"crossref","unstructured":"Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol. 1998;82(8):961\u2013965.","DOI":"10.1016\/S0002-9149(98)00627-4"},{"issue":"4 Pt 1","key":"813_CR60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0895-7061(97)00491-3","volume":"11","author":"K Kassler-Taub","year":"1998","unstructured":"Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan\/Losartan Study Investigators. Am J Hypertens. 1998;11(4 Pt 1):445\u201353.","journal-title":"Am J Hypertens"},{"issue":"1","key":"813_CR61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/080370598437574","volume":"7","author":"OK Andersson","year":"1998","unstructured":"Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998;7(1):53\u20139.","journal-title":"Blood Press"},{"issue":"5","key":"813_CR62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0149-2918(96)80040-3","volume":"18","author":"S Oparil","year":"1996","unstructured":"Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18(5):797\u2013810.","journal-title":"Clin Ther"},{"issue":"1","key":"813_CR63","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1097\/00004872-199507001-00004","volume":"13","author":"RL Byyny","year":"1995","unstructured":"Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens Suppl. 1995;13(1):S29\u201333.","journal-title":"J Hypertens Suppl"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00813-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:01:54Z","timestamp":1786172514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00813-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":63,"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00813-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"At the time the study was being conducted, all authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jing Liu conceptualized and designed the study. Jing Liu, Jialu Geng, Jiakun Liu, and Lei Hu prepared the first draft of the manuscript. Huimin Du, Ivan Tjong A. Hung, and Jia Fang performed the literature search, data extraction, and statistical analyses. All authors critically commented on and revised the manuscript and gave the final approval.","order":2,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}